LILRB4 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12202895-B2
Application number	US-201917275838-A
Country	US
Kind code	B2
Filing date	Sep 12, 2019
Priority date	Sep 13, 2018
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

First claim

What is claimed is:

1. An isolated monoclonal antibody or an antigen-binding fragment thereof comprising:
(a) a heavy chain (HC) variable region (VH) comprising:
a heavy chain complementarity determining region (HC-CDR) 1 having the amino acid sequence set forth in SEQ ID NO: 100,
a HC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 101, and
a HC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 102, 224 or 227;
and

(b) a light chain (LC) variable region (VL) comprising:
a light chain complementarity determining region (LC-CDR) having the amino acid sequence set forth in SEQ ID NO: 104,
a LC-CDR2 having the amino acid sequence of KAS or set forth in SEQ ID NO: 233, and
a LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 105 or 234.

2. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , wherein the isolated monoclonal antibody is a rabbit, a chimeric, or humanized antibody.

3. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment is a recombinant ScFv (single chain fragment variable) antibody, Fab fragment, F(ab′)2 fragment, or Fv fragment.

4. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , wherein the isolated monoclonal antibody is a rabbit or a chimeric antibody.

5. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 4 , wherein (a) the VH has the amino acid sequence at least 90% identical to SEQ ID NO: 99; and (b) the VL has the amino acid sequence at least 90% identical to SEQ ID NO: 103.

6. The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 4 , wherein (a) the VH has the amino acid sequence set forth in SEQ ID NO: 99; and (b) the VL has the amino acid sequence set forth in SEQ ID NO: 103.

7. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 1 , wherein the isolated monoclonal antibody is a humanized antibody.

8. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 7 , wherein (a) the VH has the amino acid sequence at least 90% identical to SEQ ID NO: 223, 225, 226, 228, 229, 230 or 231; and (b) the VL has the amino acid sequence at least 90% identical to SEQ ID NO: 232, 235, 236 or 237.

9. The isolated monoclonal antibody or an antigen binding fragment thereof of claim 7 , wherein (a) the VH has the amino acid sequence set forth in SEQ ID NO: 223, 225, 226, 228, 229, 230 or 231; and (b) the VL has the amino acid sequence set forth in SEQ ID NO: 232, 235, 236 or 237.

10. A pharmaceutical composition comprising the isolated monoclonal antibody or an antigen-binding fragment thereof according to claim 1 , and a pharmaceutically acceptable carrier.

11. An isolated nucleic acid that encodes the isolated monoclonal antibody according to claim 1 .

12. A vector comprising the isolated nucleic acid of claim 11 .

13. A host cell comprising the vector of claim 12 .

14. The host cell of claim 13 , wherein the host cell is a mammalian cell.

15. The host cell of claim 13 , wherein the host cell is a CHO cell.

16. A process of producing an antibody, comprising culturing the host cell of claim 13 under conditions suitable for expressing the antibody, and recovering the antibody.

17. A hybridoma encoding or producing the isolated monoclonal antibody according to claim 1 .

18. A chimeric antigen receptor (CAR) protein comprising an antigen-binding fragment according to claim 1 .

19. An isolated nucleic acid that encodes a CAR protein of claim 18 .

20. A vector comprising the isolated nucleic acid of claim 19 .

21. An engineered cell comprising the isolated nucleic acid of claim 19 .

22. The engineered cell of claim 21 , wherein the cell is a T cell, NK cell, or macrophage.

23. A method of treating or ameliorating the effect of a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof according to claim 1 or an engineered cell expressing said antibody or the antigen binding fragment thereof.

24. The method of claim 23 , wherein the method reduces or eradicates the tumor burden in the subject.

25. The method of claim 23 , wherein the method reduces the number of tumor cells.

26. The method of claim 23 , wherein the method eradicates the tumor in the subject.

27. The method of claim 23 , wherein the cancer is a hematologic malignancy.

28. The method of claim 27 , wherein the hematologic malignancy is selected from the group consisting of myelodysplastic syndromes, myeloproliferative neoplasms, chronic myelomonocytic leukemia (CMML), chronic myelocytic leukemia, acute myeloid leukemia (AML) acute myeloblastic leukemia, and polycythemia vera.

29. The method of claim 23 , wherein the antibody or an antigen-binding fragment thereof is administered intravenously, intra-arterially, intra-tumorally, or subcutaneously.

30. The method of claim 25 , further comprising administering to the subject one or more drugs selected from the group consisting of a topoisomerase inhibitor, an anthracycline topoisomerase inhibitor, an anthracycline, a daunorubicin, a nucleoside metabolic inhibitor, a cytarabine, a hypomethylating agent, a low dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, a daunorubicin and cytarabine liposome for injection, 1:5 Daunorubicin: cytarabine, an azacytidine, Azacitidine, a decitabine, an all-trans-retinoic acid (ATRA), an arsenic, an arsenic trioxide, a histamine dihydrochloride, Histamine Dihydrochloride, an interleukin-2, an aldesleukin, Interleukin-2 (IL-2), a gemtuzumab ozogamicin, Gemtuzumab ozogamicin, an FLT-3 inhibitor, a midostaurin, Midostaurin, a clofarabine, a farnesyl transferase inhibitor, a decitabine, an IDH1 inhibitor, an ivosidenib, Ivosidenib, an IDH2 inhibitor, an enasidenib, Enasidenib, a smoothened (SMO) inhibitor, a glasdegib, an arginase inhibitor, an IDO inhibitor, an epacadostat, a BCL-2 inihbitor, a venetoclax, Venetoclax, a platinum complex derivative, oxaliplatin, a kinase inhibitor, a tyrosine kinase inhibitor, a PI3 kinase inhibitor, a BTK inhibitor, an ibrutinib, Ibrutinib, an acalabrutinib, Acalabrutinib, a zanubrutinib, a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, a LAG3 antibody, an ICOS antibody, a TIGIT antibody, a TIM3 antibody, a CD40 antibody, a 4-1BB antibody, a CD47 antibody, a SIRP1α antibody or fusions protein, an antagonist of E-selectin, an antibody binding to a tumor antigen, an antibody binding to a T-cell surface marker, an antibody binding to a myeloid cell or NK cell surface marker, an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, and a P-glycoprotein inhibitor.

31. The method according to claim 23 , wherein said isolated monoclonal antibody or an antigen binding fragment thereof further comprises an antitumor drug linked thereto.

32. The method of claim 31 , wherein said antitumor drug is linked to said antibody through a photolabile linker.

33. The method of claim 31 , wherein said antitumor drug is linked to said antibody through an enzymatically-

Assignees

• Univ Texas
• Immune Onc Therapeutics Inc

Inventors

• An Zhiqiang
• Zhang Chengcheng
• Zhang Ningyan
• Gui Xun
• Deng mi
• Huang Tao
• Liu Qiang
• Liao X Charlene

Classifications

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title